These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7534978)

  • 1. A phase II study of fazarabine in patients with advanced ovarian cancer. A Gynecologic Oncology Group study.
    Manetta A; Blessing JA; Look KY
    Am J Clin Oncol; 1995 Apr; 18(2):156-7. PubMed ID: 7534978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of edatrexate in previously treated ovarian cancer. A Gynecologic Oncology Group study.
    Broun ER; Iseminger KA; Bookman M
    Am J Clin Oncol; 1995 Apr; 18(2):164-6. PubMed ID: 7900709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of fazarabine (NSC 281272) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.
    Manetta A; Blessing JA; Mann WJ; Smith DM
    Am J Clin Oncol; 1995 Oct; 18(5):439-40. PubMed ID: 7572764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of fazarabine (NSC 281272) in patients with metastatic colon cancer.
    Ben-Baruch N; Denicoff AM; Goldspiel BR; O'Shaughnessy JA; Cowan KH
    Invest New Drugs; 1993 Feb; 11(1):71-4. PubMed ID: 7688714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study.
    Thigpen JT; Blessing JA; Olt G; Lentz SS; Bell J
    Gynecol Oncol; 2003 Sep; 90(3):581-6. PubMed ID: 13678728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study.
    Plaxe SC; Blessing JA; Bookman MA; Creasman WT
    Gynecol Oncol; 2002 Jan; 84(1):32-5. PubMed ID: 11748972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
    Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
    Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of merbarone (NSC 336628) in the treatment of recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.
    Look KY; Blessing JA; Adelson MD; Morris M; Bookman MA
    Am J Clin Oncol; 1996 Feb; 19(1):7-9. PubMed ID: 8554040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer.
    Brown JV; Peters WA; Rettenmaier MA; Graham CL; Smith MR; Drescher CW; Micha JP
    Gynecol Oncol; 2003 Feb; 88(2):136-40. PubMed ID: 12586592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.
    Markman M; Blessing JA; Alvarez RD; Hanjani P; Waggoner S; Hall K
    Gynecol Oncol; 2000 Apr; 77(1):112-5. PubMed ID: 10739699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group.
    Hochster H; Wadler S; Runowicz C; Liebes L; Cohen H; Wallach R; Sorich J; Taubes B; Speyer J
    J Clin Oncol; 1999 Aug; 17(8):2553-61. PubMed ID: 10561322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of fazarabine in refractory pediatric solid tumors. A Pediatric Oncology Group study.
    Bernstein ML; Whitehead VM; Grier H; Dubowy R; Land V; Devine S; Murphy S; Kung F
    Invest New Drugs; 1993 Nov; 11(4):309-12. PubMed ID: 7512539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
    Miller DS; Blessing JA; Waggoner S; Schilder J; Sorosky J; Bloss J; Schilder R
    Gynecol Oncol; 2005 Jan; 96(1):67-71. PubMed ID: 15589582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group.
    van Wijk FH; Lhommé C; Bolis G; Scotto di Palumbo V; Tumolo S; Nooij M; de Oliveira CF; Vermorken JB;
    Eur J Cancer; 2003 Jan; 39(1):78-85. PubMed ID: 12504662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116).
    Oza AM; Elit L; Swenerton K; Faught W; Ghatage P; Carey M; McIntosh L; Dorr A; Holmlund JT; Eisenhauer E;
    Gynecol Oncol; 2003 Apr; 89(1):129-33. PubMed ID: 12694666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
    Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
    Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
    Hochster H; Plimack ER; Runowicz CD; Speyer J; Wallach RC; Sorich J; Mandeli J; Wadler S; Wright J; Muggia FM
    J Clin Oncol; 2004 Jan; 22(1):120-6. PubMed ID: 14701774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A; Blessing J; Bender D; Mannel R; Morgan M;
    Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.